| Title |
Outcomes, Access, and Cost Issues Involving PCSK9 Inhibitors to Lower LDL-Cholesterol
|
|---|---|
| Published in |
Drugs, February 2018
|
| DOI | 10.1007/s40265-018-0867-9 |
| Pubmed ID | |
| Authors |
Thomas F. Whayne |
| Abstract |
The clinical importance and benefit of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors appears well established for the high-risk cardiovascular (CV) patient. This applies especially to the statin-intolerant patient or the patient who does not attain an appropriate low-density lipoprotein cholesterol (LDL-C) target. Therefore, the barriers to appropriate clinical use of the PCSK9 inhibitors involve cost and not the documented CV benefit or LDL-C lowering. Multiple roadblocks affect many high-risk CV patients in arranging approval of a PCSK9 inhibitor. Overcoming these roadblocks may require legal pressures, some increased regulation, and facilitation by competitive forces. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 33% |
| United States | 1 | 33% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 15 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 15 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 3 | 20% |
| Student > Ph. D. Student | 2 | 13% |
| Student > Bachelor | 2 | 13% |
| Student > Master | 2 | 13% |
| Other | 1 | 7% |
| Other | 1 | 7% |
| Unknown | 4 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 3 | 20% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 13% |
| Nursing and Health Professions | 1 | 7% |
| Business, Management and Accounting | 1 | 7% |
| Agricultural and Biological Sciences | 1 | 7% |
| Other | 1 | 7% |
| Unknown | 6 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 April 2018.
All research outputs
#13,503,921
of 23,020,670 outputs
Outputs from Drugs
#2,601
of 3,288 outputs
Outputs of similar age
#217,521
of 439,370 outputs
Outputs of similar age from Drugs
#20
of 28 outputs
Altmetric has tracked 23,020,670 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,288 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one is in the 20th percentile – i.e., 20% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 439,370 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.
We're also able to compare this research output to 28 others from the same source and published within six weeks on either side of this one. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.